secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2026-08-04T20:10:16+00:00
Accession:  0001034842-26-000053
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q2 net product sales $67M (+14% YoY); raises 2026 revenue guidance to $285-295M; in-licenses VEPPANU
--------------------------------------------------------------------------------

- Q2 2026 total revenues $78.7M, net income $17.3M ($0.88 diluted EPS); prior year net income $59.6M included $40M non-cash Lilly revenue.
- TAVALISSE sales $47.4M (+18% YoY), REZLIDHIA $8.9M (+27%), GAVRETO $10.7M (-10%).
- In-licensed VEPPANU (vepdegestrant) from Arvinas/Pfizer for $70M upfront; U.S. launch expected mid-August 2026.
- 2026 revenue guidance raised to $285-295M (ex-VEPPANU) from $275-290M; contract revenue guidance increased to ~$30M.
- Cash & investments $95.3M at June 30, 2026, down from $155.0M at Dec 31, 2025 due to VEPPANU upfront payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000053/0001034842-26-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000053/rigl-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001034842-26-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer